Late 2024 to 2025 : After a GLP-1 NAION study was published potentially linking semaglutide GLP-1 medications to a higher risk of developing NAION, lawsuits and investigations began focusing on whether manufacturers failed to adequately warn about the risk of sudden vision loss, optic nerve damage, and permanent blindness
Posibilidades de uso de arGLP-1 en Espaa para el tratamiento de la obesidad La figura 2 plantea grficamente las opciones existentes a da de hoy para el control del peso en Espaa, que son aplicables a los pacientes que, adems, sufren PsO o HS
For a quick comparison, heres an overview of the nutritional and pricing details: *While exact nutritional details arent provided, these options are designed with blood sugar awareness in mind
And in one of the studies, 16 of the 45 participants dropped out before the study ended
Gestrelius S, Andersson C, Lidstrom D, Hammarstrom L, Somerman M